FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1207-1209 April 15, 1999 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by McHutchison, J. G.

To the Editor: Two studies in the November 19 issue, one by McHutchison et al.¹ and one by Davis et al.,² were supported by Schering-Plough and show that combining interferon alfa-2b with ribavirin leads to better virologic and biochemical rates of response in patients with hepatitis C. The cost to the patient of a 48-week course of this drug combination (Rebetron, Schering-Plough, Kenilworth, N.J.) is about $18,000. The side effects of an initial course of treatment are considerable: in the study by McHutchison et al., about two thirds of patients had influenza-like symptoms, and about one third each had nausea, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.